Company intelligence / Profile preview

Sumitovant Biopharma

New York City, New York, United Statesus.sumitomo-pharma.com ↗

Ownership: Private
Employees: ~246
Development stage: Commercial

Overview

Sumitovant supported the development of multiple FDA-approved products including ORGOVYX® for prostate cancer and GEMTESA® for overactive bladder. Its portfolio included both commercialized drugs and a robust pipeline addressing unmet needs in pediatrics, urology, oncology, women’s health, specialty respiratory diseases, and infectious diseases.

Therapeutic areas: PulmonologyUrologyWomen's HealthOncologyRare Diseases
Modalities: Small moleculeMonoclonal antibodyGene therapyCell therapyRNA therapy
Industry: Pharma

Drug pipeline

1 asset

ALTA-2350

Unknown

Partnerships

Pfizer partnership with Myovant on relugolix/ORGOVYX® commercialization in oncology/women's health in US/Canada; Pfizer option ex-US/excluded Asia.

Beyond the preview

Go deeper on Sumitovant Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sumitovant Biopharma.

Explore the full profile